	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	1,465	1,520	1,863	2,056	3,123	3,105	3,130	3,935	4,606	5,393	5,306	5,653	6,229	6,672	7,345
Cost of Operating Revenue	742	778	754	846	1,001	1,078	1,137	1,264	1,390	1,647	1,871	2,268	2,338	2,444	2,303
Gross Profit	724	742	1,109	1,210	2,122	2,027	1,993	2,671	3,215	3,746	3,435	3,384	3,891	4,228	5,042
Gross Margin	49.4	48.8	59.5	58.9	67.9	65.3	63.7	67.9	69.8	69.5	64.7	59.9	62.5	63.4	68.6
Total Operating Expenses	1,280	1,306	1,546	1,703	2,190	2,567	2,620	3,194	3,495	4,096	4,718	5,215	5,568	5,942	6,545
Operating Profit	186	214	317	353	933	538	510	741	1,111	1,297	587	438	661	730	800
Operating Margin	12.7	14.1	17.0	17.2	29.9	17.3	16.3	18.8	24.1	24.0	11.1	7.7	10.6	10.9	10.9
Financing Income/(Expense) - Net	-26	-11	-10	4	-2	-10	26	5	11	84	49	1	-35	-48	-94
Profit before Taxes	161	206	311	359	936	529	541	749	1,000	1,368	620	355	632	707	694
Income Taxes	31	41	75	76	216	122	120	157	199	253	104	13	16	125	23
Profit after Tax	130	165	236	283	720	403	413	584	829	1,147	521	342	616	583	675
PAT Margin	8.9	10.9	12.6	13.8	23.1	13.0	13.2	14.9	18.0	21.3	9.8	6.0	9.9	8.7	9.2
EPS - Basic - ex Extraordinary Items	6.89	8.77	12.49	15.01	38.19	21.39	21.89	31.00	43.97	59.18	26.50	17.40	31.33	29.68	34.33
EPS - Diluted - ex Extraordinary Items	6.89	8.77	12.49	15.01	38.19	21.39	21.89	31.00	43.97	59.18	26.50	17.40	31.33	29.68	34.33
EBIT	186	214	317	353	933	538	510	741	1,111	1,297	587	438	661	730	800
EBITDA	219	249	358	398	1,005	621	615	856	1,268	1,480	874	713	933	1,008	1,118
EBITDA Margin	15.0	16.4	19.2	19.3	32.2	20.0	19.7	21.8	27.5	27.4	16.5	12.6	15.0	15.1	15.2

Balance Sheet

Abridged

Understanding Balance Sheet

Alembic Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	688	632	670	922	1,511	1,372	1,825	1,958	2,463	2,652	2,861	2,910	3,079	4,088	4,573
Long-Term Investments	3	3	33	52	33	0	0	0	0	0	64	71	69	101	113
Property Plant & Equipment - Net	326	376	418	572	801	1,169	1,838	2,440	3,099	3,647	3,947	3,000	3,071	3,361	3,477
Total Non-Current Assets	364	416	493	699	917	1,317	2,116	2,820	3,526	4,057	4,261	3,273	3,367	3,685	4,190
Total Assets	1,052	1,048	1,162	1,621	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,773	8,763
Total Current Liabilities	654	488	438	592	747	693	1,123	1,490	1,752	1,281	1,717	1,637	1,455	2,412	2,594
Long Term Debt	95	71	52	19	-	-	500	499	960	271	72	69	63	47	167
Total Non-Current Liabilities	122	103	94	65	84	94	597	570	1,047	361	168	175	172	171	500
Total Liabilities	776	591	533	657	831	787	1,721	2,060	2,799	1,642	1,884	1,812	1,627	2,583	3,094
Total Shareholders' Equity	395	503	630	964	1,597	1,902	2,220	2,719	3,219	5,067	5,238	4,370	4,818	5,191	5,675
Minority Interest	-	-	-	-	-	0	0	-1	-29	-	-	-	-	-1	-6
Total Equity	395	503	630	964	1,597	1,902	2,220	2,718	3,190	5,067	5,238	4,370	4,818	5,190	5,669
Total Liabilities & Equity	1,171	1,094	1,162	1,621	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,773	8,763

Cash Flow

Abridged

Understanding Cash Flow Statement

Alembic Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	171	211	298	316	806	490	469	638	934	1,157	872	733	853	937	953
Working Capital - Increase/(Decrease)	-62	44	-72	-158	139	-166	-181	109	-593	240	-367	-58	-96	-921	-257
Net CF from Operating Activities	109	254	226	158	945	325	288	746	341	1,397	505	675	757	16	696
Capital Expenditures - Net	61	85	82	201	301	491	807	763	734	659	424	442	316	554	493
Net CF from Investing Activities	-61	-85	-82	-235	-309	-487	-886	-760	-734	-845	-377	-449	-324	-575	-507
Dividends Paid - Cash - Total	22	30	55	66	79	90	91	91	326	-	275	197	157	216	216
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	734	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	14	-170	-85	144	-132	-39	619	221	161	-398	110	-17	-231	739	141
Net Cash Flow from Financing Activities	-7	-200	-140	77	-219	-124	529	129	266	-524	-165	-212	-389	522	-76
Free Cash Flow to Equity	62	-1	59	102	511	-205	99	204	-233	340	191	216	210	201	344
Free Operating CF net dividend	26	138	89	-108	565	-276	-625	-109	-720	737	-196	35	273	-764	-15
Free Operating CF	48	168	144	-43	644	-186	-534	-18	-394	737	79	232	430	-548	201

Business Segment Analysis

FY End:

Mar 25

Alembic Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 563.62 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 6,672.08 Cr

Assets

Pharmaceuticals (100.0%)₹ 7,772.94 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 729.74 Cr

Regional Segment Analysis

Alembic Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Alembic Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Alembic Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	735	660	426	443	327	564

Frequently Asked Questions

What is the revenue of Alembic Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Alembic Pharmaceuticals Ltd. is ₹ 7,344.90 Cr, reflecting a 1-year growth of 10.08% and a 3-year CAGR of 9.12%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Alembic Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Alembic Pharmaceuticals Ltd. is ₹ 674.77 Cr, with a 3-year earnings CAGR of 25.43%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Alembic Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Alembic Pharmaceuticals Ltd. is approximately ₹ 799.91 Cr (based on an operating margin of 10.89%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Alembic Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Alembic Pharmaceuticals Ltd. is 34.33. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Alembic Pharmaceuticals Ltd.?

The debt-to-equity ratio of Alembic Pharmaceuticals Ltd. stands at 0.25. The interest coverage ratio is 8.54x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Alembic Pharmaceuticals Ltd.?

The estimated book value per share of Alembic Pharmaceuticals Ltd. is 288.70 (derived from a P/B ratio of 2.81 and market price of ₹ 811.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Alembic Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Alembic Pharmaceuticals Ltd. is ₹ 695.72 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Alembic Pharmaceuticals Ltd. report consolidated or standalone financials?

Alembic Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.